Progress on experimental models of neuromyelitis optica spectrum disease. [PDF]
Yawen G +5 more
europepmc +1 more source
Global landscape of neuromyelitis optica spectrum disorder clinical trials: trends in therapies, geography, and outcomes. [PDF]
Wang G +7 more
europepmc +1 more source
Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report. [PDF]
Ding M +5 more
europepmc +1 more source
Pseudoathetotic Pseudodystonia as a Manifestation of Isolated Medullary Demyelination in Neuromyelitis Optica Spectrum Disorder. [PDF]
Mohapatra P +8 more
europepmc +1 more source
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. [PDF]
Furlan R +28 more
europepmc +1 more source
A case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica. [PDF]
Zhang M, Liu X, Cheng S, Ruan Y.
europepmc +1 more source
Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series. [PDF]
Hu S +6 more
europepmc +1 more source
HLA Associations Differ by Ethnicity and Aquaporin-4 Antibody Status in Patients With Neuromyelitis Optica Spectrum Disorders. [PDF]
Niederschweiberer M +19 more
europepmc +1 more source
Longitudinal retinal microvascular changes and their association with white matter hyperintensities in neuromyelitis optica spectrum disorder. [PDF]
Liu Y +8 more
europepmc +1 more source
Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series. [PDF]
Deng M +6 more
europepmc +1 more source

